The company obtained an exclusive, worldwide license from Harvard Medical School’s Beth Israel Deaconess Medical Center in February 2005 for the development of a “super” EPO, a more potent and longer acting form of Erythropoietin.
“GMP (good manufacturing practices) manufacturing is the next step in our R&D of PT-401,” stated DNAPrint president and CEO Richard Gabriel. “The GMP material produced by KBI BioPharma will be used to conduct preclinical studies required for a future investigational new drug application, including toxicology studies and studies involving volunteers and patients.”
The company’s goal is to utilize recent genomics and chemistry advances to develop next-generation test/drug combinations called “theranostics,” designed to maximize efficacy and minimize side effects by tailoring and customizing medication for specific individuals and well-defined population sectors.